Sen. Kay Hagan's proposal to set up an accelerated approval pathway for experimental medications hasn't been universally embraced by everyone in the biopharma industry. And a contributing Forbes columnist claims that he knows why: Big Pharma forces helped scuttle an initial proposal that could have triggered a major retooling of the approval process, significantly restructuring the relationship that exists between pharma companies and the biotech companies that often deliver their most innovative treatments.
In an in-depth article, the News & Observer notes that the National Organization for Rare Disorders, The Friends of Cancer Research, Parkinson's Action Network and the Biotechnology Industry Organization all lined up behind the TREAT Act, which promises to accelerate the approval process for developers who can prove that they can potentially treat an unmet medical need or significantly advance the standard of care for people suffering from deadly diseases. But PhRMA and its Big Pharma allies appear to be standing on the sidelines for now.
In a column in Forbes today, though, Avik Roy--a frequent critic of government bureaucracy and left-wingers of all stripes--maintains that the new TREAT Act is a pale version of its original form. Initially, he writes, Hagan, a North Carolina Democrat, had sought to offer a proposal that would have allowed developers to go after a provisional approval with Phase II data.
"Sen. Hagan's proposal would have been devastating to the big pharma R&D oligopoly," writes Roy. "If small biotech companies could get their drugs tentatively approved after inexpensive phase II studies, they would have far less need to partner those drugs with big pharma. They could keep the upside themselves and attract far more interest from investors. Big pharma, on the other hand, would be without its largest source for innovative new medicines: the small biotech farm team."
So PhRMA and the big companies moved to water the TREAT Act down, Roy claims. The new act "merely allows for the existing, surrogate marker-driven accelerated approval process to address 'highly targeted therapies for distinct subpopulations.'"
Erik Gordon, a biomedical expert and business professor at the University of Michigan, told the News & Observer that the bill still has the potential to make biotechs less dependent on Big Pharma, which typically picks up a program and carries it through the expensive late-stage study.
"Smaller biotech companies often can't raise enough money on their own to do the currently-required safety trials, so they want to dilute the rules to let them get approvals without having to give big pharma a cut of the action in return," Gordon told Bloomberg a few weeks ago. "Big pharma says 'don't dilute safety measures for new drugs.' That sounds better than 'we want to keep our cut of the action.'"